Serum phospholipids are potential biomarkers for the early diagnosis of gastric cancer

Long Zou,Lei Guo,Cheng Zhu,Zhizhen Lai,Zhili Li,Aiming Yang
DOI: https://doi.org/10.1016/j.cca.2021.05.002
IF: 6.314
2021-08-01
Clinica Chimica Acta
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and aims</h3><p>Early diagnosis is key to improving the prognosis of gastric cancer. Altered phospholipid metabolism has been observed in different types of cancer. This study assessed serum phospholipid levels of patients with gastric cancer to explore biomarkers for its early diagnosis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>A total of 199 participants were enrolled, including patients with early gastric cancer or precancerous gastric lesions and healthy controls. Serum phospholipids were extracted and identified using mass spectrometry. The relative abundances of these phospholipids were compared among patients at different disease stages. Twenty-four patients with early gastric cancer were followed up, and their serum phospholipid levels were compared beween before and after resection.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Fifty-four phospholipids were identified. Phosphatidylethanolamine (36:3), phosphatidylethanolamine (36:2), phosphatidylcholine (32:0), and sphingomyelin (d18:0/18:1(9Z)) were more abundant in patients with early gastric cancer than in healthy controls. The area under the receiver operating curve of sphingomyelin (d18:0/18:1(9Z)) reached 0.883 in the training set (sensitivity 81.08%, specificity 78.82%) and 0.874 in the validation set. The levels of phosphatidylethanolamine (36:2), phosphatidylcholine (32:0), and sphingomyelin (d18:0/18:1(9Z)) significantly declined after the cancerous lesions were resected.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Serum phospholipids can serve as potential biomarkers for the early diagnosis of gastric cancer.</p>
medical laboratory technology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore biomarkers that can be used for the early diagnosis of gastric cancer by evaluating the phospholipid levels in the serum of gastric cancer patients. Specifically, the study focuses on the differences in serum phospholipid levels between early - stage gastric cancer patients and healthy control groups, as well as the changes in these phospholipid levels at different disease stages. In addition, the study also explores the changes in specific phospholipid levels before and after the resection of cancerous lesions to evaluate their potential value as early gastric cancer diagnosis and surgical effect monitoring. The research background indicates that early diagnosis is crucial for improving the prognosis of gastric cancer. Alterations in phospholipid metabolism have been observed in different types of cancers. Therefore, this study aims to discover biomarkers that can be used for the early diagnosis of gastric cancer by detecting and comparing the relative abundances of serum phospholipids in patients at different disease stages.